Early top-down anti-TNF treatment from diagnosis was associated with improved long-term outcomes at 5 years compared with step-up treatment and is suggestive of a disease-modifying effect in Crohn's disease.

Researchers uncover a new genetic marker that is associated with more severe inflammatory bowel disease (IBD), suggesting these patients could benefit from receiving advanced treatment more quickly.

Single-cell mapping of cis-expression quantitative trait loci in inflammatory bowel disease revealed distal, enhancer-enriched variants detected at the cell-type level more frequently co-localize with genome-wide association study loci than those identified at the tissue level.

Nature Reviews Gastroenterology & Hepatology, Published online: 08 April 2026; doi:10.1038/s41575-026-01199-4Drug classes offer convenient clinical shorthand but obscure meaningful differences between individual therapies in inflammatory bowel disease. As treatment options expand, moving beyond class effects towards drug-level selection informed by pharmacology, efficacy, safety and patient context is essential to deliver more precise care.

The human gut epithelium performs vital absorptive functions, while simultaneously forming a physical barrier between the gut contents and the body. As such it is essential for health and its dysregul...

Crohn's disease (CD) is a heterogeneous disease characterized by chronic inflammation of the gastrointestinal tract driven by an aberrant immune response. To understand the immune mechanisms underlyin...

Fang and colleagues show that the metabolite succinate can inhibit succinylation, and consequently protection from ubiquitin-mediated degradation, of the transcription factor FOXP3, with consequences ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) poses a significant global health challenge due to its rising prevalence and strong association with metabolic syndrome and type 2 diab...

Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding therapeutic armamentarium and the increasingly ambitious treatment targets...

Nature Reviews Gastroenterology & Hepatology, Published online: 22 April 2025; doi:10.1038/s41575-025-01063-xInflammatory bowel disease (IBD) is an immune-mediated disease with substantial burden worldwide. In this Consensus Statement, a global multidisciplinary group of experts identify key priorities and recommendations to raise awareness and advance IBD care and research.

Therapeutic progress in inflammatory bowel disease (IBD) has hitherto focused on reducing inflammation to minimise long-term complications. However, strategies aimed at preventing IBD and attenuating ...

Take this survey powered by surveymonkey.com. Create your own surveys for free.

Mirikizumab is a monoclonal antibody directed against the p19 subunit of interleukin (IL)-23 to inhibit its interaction with the IL-23 receptor. IL-23 is a key cytokine involved in initiating and perp...